“ No CRS, ICANS, infections or severe hostile occasions noticed in both of the primary two sufferers by way of…
Goal response fee of 39% with manageable security profile in sufferers with non-small cell lung most cancers (NSCLC) harboring EGFR…
Akebia Therapeutics (NASDAQ: NASDAQ:) mentioned its Q1 2024 monetary outcomes and the strategic initiatives for the launch of its anemia…
Non-public social networking is making a comeback. Gratitude Plus, a startup that goals to shift social media in a extra…
Our selection of the week's biggest research news and features sent directly to your inbox. Enter your email address, confirm you're happy to receive our emails.
Please contact salesdepartment
for further information at:
Sales@88.broker
Sign in to your account